Table 3.

Multivariate analysis of prognostic factors for PFS in mCRC patients treated with oxaliplatin-based chemotherapy

Model 1			Model 2
Variables	HR (95% CI)	P value	Variables	HR (95% CI)	P value
Tumor location			Tumor location
Colon vs. Rectum	0.77 (0.39-1.54)	0.46	Colon vs. Rectum	0.77 (0.39-1.52)	0.45
Depth of invasion			Depth of invasion
pT2/pT3 vs. pT4	0.90 (0.47-1.72)	0.74	pT2/pT3 vs. pT4	0.90 (0.48-1.72)	0.76
Lymph node metastasis			Lymph node metastasis
pN0/pN1 vs. pN2	0.94 (0.50-1.77)	0.86	pN0 vs. pN1/pN2	0.94 (0.51-1.72)	0.83
Lymphatic invasion			Lymphatic invasion
ly0/ly1 vs. ly2/ly3	0.87 (0.43-1.81)	0.72	ly0/ly1 vs. ly2/ly3	0.88 (0.43-1.81)	0.73
Venous invasion			Venous invasion
v0/v1 vs. v2/v3	1.15 (0.59-2.23)	0.68	v0/v1 vs. v2/v3	1.15 (0.60-2.24)	0.67
OCT2			Combined OCT2 and TB
Low vs. High	0.44 (0.24-0.80)	0.007*	Two favorable factors vs.	0.43 (0.26-0.70)	0.001*
TB			One favorable factor vs.
Low vs. High	2.38 (1.31-4.30)	0.004*	No favorable factors

^*Statistically significant;

PFS, progression-free survival; mCRC, metastatic colorectal cancer; HR, hazard ratio; CI, confidence interval; OCT2, organic cation transporter 2; TB, tumor budding.